anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1347950 Aerosol antiperspirants BRISTOLMYERS CO 7 March 1972 [8 March 1971] 10555/72 Heading C4X [Also in Division A5] Anhydrous aerosol antiperspirant compositions comprise a powdered aluminium antiperspirant mix distributed in a liquid vehicle comprising a non-volatile, organic, oily liquid having a boiling point under atmospheric pressure not lower than 120‹ C. and a specific gravity of 0À7 to 1À6, and an aerosol propellant, the powdered aluminium antiperspirant mix comprising aluminium chloride and a water soluble antiperspirant aluminium salt less acidic than aluminium chloride, e.g. aluminium chlorhydroxide, aluminium sulphate, aluminium chlorhydroxide-propylene glycol complex, complex of zinc phenol sulphonate and chlorhydrol, aluminium potassium sulphate and aluminium chlorhydroxide-polyethylene glycol mixture. The organic oily liquid may be a liquid hydrocarbon (e.g. mineral oil, Iso-Par); a fatty acid ester (e.g. isopropyl myristate, isopropyl palmitate): a diester of a dicarboxylic acid (e.g. diisopropyl adipate); a polyoxyalkylene glycol ester (e.g. polypropylene glycol 2000 monooleate): a propylene glycol diester of a short chain fatty acid (C 8-10 ) (e.g. Neobeer); a polyoxyethylene ether (e.g. polyoxyethylene (4) lauryl ether, polyoxyethylene (2) oleyl ether, polyoxyethylene (10) oleyl ether); a polyoxypropylene cetyl ether (e.g. Procetyl); a fatty alcohol (e.g. oleyl, hexadecyl, lauryl alcohols); a propoxylated monohydric alcohol. M.W. 880- 930, and/or a silicone oil (e.g. dimethyl polysiloxane). The propellant may be trichloromonofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethane, trichlorotrifluoroethane, propane, butane, pentane and/or isobutane. The compositions may also contain a suspending agent such as a fumed silica, dimethyl dioctadecyl ammonium bentonite, magnesium aluminium silicate, polyethylene powder, aluminium stearate or aluminium octoate, an antibacterial or antifungal agent such as hexachlorophene, quaternary nitrogen compounds, benzoic acid, resorcinol monoacetate, chlorobutanol, Vancide and zinc omadine; a fragrance, a slip agent such as talc or zinc stearate; a surfactant such as sorbitan monooleate, a pigment such as titanium dioxide; a fabric damage reducing agent such as urea or glycine; and/or an anticorrosion agent such as ethoxylated dinonyl phenyl mono and diester of phosphoric acid; propoxylated cetyl mono and diesters of phosphoric acid and epoxidized butyl esters of linseed oil fatty acids. The powdered aluminium antiperspirant mix may be prepared by forming an aqueous solution containing aluminium chloride and a water soluble antiperspirant aluminium salt less acidic than aluminium chloride, drying the solution to obtain a dry product and optionally pulverizing the dry product to produce a powder suitable for suspension in an aerosol container.
Patients in the nCIT group will receive two cycles of TC chemotherapy combined with immunotherapy, specifically paclitaxel (albumin-bound) 100 mg/m² on days 1, 8, 15 or 260mg/m² d1, carboplatin (AUC=5) on days 1, and toripalimab (200 mg) on days 1. Minimally invasive esophagectomy will be performed 4-6 weeks after completing chemotherapy, and adjuvant immunotherapy is recommended for one year after surgery.
Impoverished communities in Lima, Peru will be offered free medical clinics. Four communities have been chosen initially for focus over the following 10 years. These communities will be made aware of their risk for chronic lifestyle related diseases. In conjunction with the communities, specific interventions focused on a plant-based diet, physical activity, stress management and control of unhealthy habits will be devised.
Polycystic ovary syndrome (PCOS) is one of the leading causes of female infertility, affecting around 5% of women with a child-bearing age in China. Vitamin D insufficiency is common in women with PCOS and is associated with lower live birth rates in these women. However, evidence regarding the effectiveness of vitamin D treatment in women with PCOS is inconclusive. This multicenter double-blinded placebo-controlled randomised trial aims to evaluate the effectiveness of vitamin D supplementation prior to IVF on the live birth rate in women with PCOS.

The investigators plan to enroll women with PCOS scheduled for IVF. Eligible participants will be randomised 1:1 to receive oral capsules of 4000IU vitamin D per day or placebo for around 12 weeks until the day of triggering. All IVF procedures will be carried out following a routine method in each center. Women will be followed up until six months after randomisation for those who fail to get pregnant after the completion of the first embryo transfer or delivery for those who get pregnant after the first embryo transfer. The primary outcome is live birth after the first embryo transfer. Primary analysis will be by intention-to-treat analysis. The investigators plan to recruit 860 women to demonstrate women treated with vitamin D have a higher live birth rate than those treated with placebo (48% versus 38%), accounting for 10% loss to follow-up with a significance level at 0.05 and a power of 80%.
PURPOSE: A method for preparing novel benzofuran-2-carboxamide derivative is provided to prevent or treat MCH receptor-1 related diseases such as obesity, diabetes, metabolic disorder, anxiety, and depression. CONSTITUTION: A benzofuran-2-carboxamide derivative is denoted by chemical formula 1. A pharmaceuticalcomposition for preventing and treating MCH receptor-1 related diseases contains the derivative or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. A food composition for preventing or treating MCH receptor-1 related diseases contains the derivative or salt of hydrate thereof as an active ingredient. A method for preparing the derivative comprises a step of reacting a compound of chemical formula 2 with a compound of chemical formula 3 in a solvent. [Reference numerals] (AA) Condensation
Individuals who tested positive for SARS-CoV2 by an objective PCR or antigen test will be recruited to evaluate smell function weekly over 3 months. All consent and testing will occur on a phone/tablet app in the participant's home.
Aim: This study was conducted to evaluate the effectiveness of the nursing support program developed for women who had hysterectomy.

Methods: A prospective, randomised controlled study was conducted in the gynaecology clinic of a university hospital between November 2017 and November 2018. It was conducted in a single-blind, randomised controlled trial with a total of 60 women in the experimental and control groups. A nursing support program had been developed for women who have had a hysterectomy. The program developed for the experimental group and the routine program for routine maintenance and control group were applied. The initial evaluation was carried out postoperative on the 1st-2nd day, the second assessment was carried out on the 6th-7th day and the third evaluation was carried out at 2 months. The first interview was carried out in the hospital, and the second and third interviews were carried out with home visits. The sociodemographic data form, postoperative evaluation form, Female Sexual Function Index (FSFI), Epidemiological Studies and Central Depression Scale (EAMDS), Menopausal Symptoms Evaluation Scale (MSDS) and SF-12 quality of life scale were used to collect data.
A standardized 3-step anticholinergic regimen of daily oral solifenacin 5mg, solifenacin 10mg, and/or trospium chloride XR 60mg, as well as a single intradetrusor injection of saline (placebo). All subjects will begin on solifenacin 5 mg for 2 mo. If a subject's symptoms are not adequately controlled at 2 mo, she will be escalated to solifenacin 10mg, and similarly at 4 mo to trospium XR 60mg. If a subject's symptoms are adequately controlled on solifenacin 5 mg, she may continue that study medication for the entirety of the study (6 mo). Additionally, if a subject is dose-escalated to solifenacin 10mg at study mo 2 or 4, and her symptoms are adequately controlled, she may continue the solifenacin 10mg dose for the remainder of the study.
Use of protease enzymes e.g. auxillase, for inhibiting mite excrement and/or mold spores, and for denaturing keratin in animal hair and/or denaturing plant pollen or spores is new. The enzymes break down the protein chain in mite excrement, keratin in animal hair or plant pollen or spores, into oligopeptides, mono-, di- or tripeptides. The decomposition product has no allergic effect on humans. Use of an active ingredient (I) for: (a) inhibiting mite excrement and/or mold spores; and (b) denaturing keratin in animal hair and/or denaturing plant pollen or spores is new. (I) is an enzyme which is capable of breaking down homogeneously the protein chain of mite excrement, of keratin in animal hair or the protein chain of plant pollen or spores, into oligopeptides, mono-, di- or tripeptides, where the decomposition product has no allergic effect on humans. ACTIVITY : Antiallergic; Acaricide.
Participants administered topical rectal budesonide foam at 2 mg/25 mL BID (morning and 12 hours later) for 2 weeks followed by 2 mg/25 mL QD (in the evenings) for 4 weeks for up to 8 cycles. After Cycle 1, participants needed to qualify to be able to participate in subsequent cycles. Participants underwent a 48-hour study drug washout period between each cycle.
The present invention relates to an aspirin slow-controlled-release capsule preparation and a preparing method thereof, which mainly comprises aspirin, sucrose, starch, alcohol, Tween-80, acrylic resin and talcum powder. 1000 capsules comprise 100 to 350 g of micro pills containing the medicines of 50, 75 or 150 g of the aspirin and 0 to 200 g of hollow micro pills. The ingredients of the prescription are prepared by the following method: the aspirin is wrapped on hollow pill cores to produce the micro pills containing the aspirin; the micro pills containing the medicines and having required particle diameters are obtained by sieving operation; release-control films are wrapped; finished products are obtained by loading the micro pills wrapped by the films into capsules. The present invention does not release the aspirin in the stomach, and releases little aspirin (lower than 0.1%) in stomach juice so as to reduce the side effect of the aspirin on the stomach. The aspirin release degree in intestinal liquid is good (close to 100%) so as to reduce the side effect. Thus, the treating effect is improved.
Cohort B1 will involve a dose escalation to evaluate atezolizumab administered in combination with ascending-dose lenalidomide in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment. NOTE: This cohort has been completed.
An electronic device and method for chronic pulmonary disease prediction from audio input based on short-winded breath determination using artificial intelligence is disclosed. The electronic device receives an audio input associated with a user. The electronic device applies an Artificial Intelligence (AI) model to detect a short-winded breath duration that corresponds to a time duration between an end of a first spoken word and a start of a second spoken word succeeding the first spoken word. The electronic device detects a speaking pattern. The electronic device applies a Recurrent neural network (RNN) model to reconstruct a set of short-winded breath audio samples. The electronic device generates an audio sample dataset and a set of audio features. The electronic device applies a modular neural network model on the generated audio sample dataset and on the generated set of audio features to determine a set of chronic obstructive pulmonary disease (COPD) metrics.
The utility model provides a digital watermarking electronic medical record supporting system which includes a database which is arranged in a hospital and is used for storing medical record files of patients in the hospital, and a digital watermarking electronic medical record interface platform which is arranged in a doctor workroom and is connected with the database. The interface platform includes a computer, and a carrier image generating device and a storage medium read-write device which are connected with the computer. The carrier image generating device is used for generating a carrier image of the medical record information. A digital watermarking electronic medical record is also provided. The digital watermarking electronic medical record includes a storage medium and a medical record file stored in the storage medium. The medical record file is a carrier image embedded with the medical record information. The system can prevent the leakage or falsification of the information recorded in the medical record, thus guaranteeing the truth and the undeniability of the recorded information.
During an open shoulder surgery, the Ceftriaxone will be administered to some patient. The Ceftriaxone is a third generation cephalosporin. It targets gram positive cocci such as staphylococcus and streptococcus, gram negative bacilli and some anaerobes, including P. acnes. The prophylactic dose is of 2g IV given a minimum of 30 minutes prior to skin incision. It is effective 12h so no other dose is needed during surgery.
Pharmaceutical compsn. for treating cerebral vascular disorders containing as active ingredient an acylacarnitine of formula (I) (where R is acetyl, propionyl, butyryl, hydroxybutyryl or acetoacetyl), or a salt, ester or amide of such acids. The compsn. are for treatment of sensile and pre-senile psycho-motor conditions, depression, reduced cerebral flood flow, results of cerebral shock, cerebral is chaemia and primary alterations of cerebral metabolism at daily doses of 2-20 mg/kg of (I). When acetylcarnitine is introduced into the lateral ventricles of the brain in the cat, a dilation of pupils and increased motor activity is induced. None of these effects are induced by intravenous injection, possibly because the cpd. does not pass the blood-brain barrier.
NEW MATERIAL:7,7-Dimethyl-2-methylenebicyclo[2.2.1]heptan-6-ol and its lower aliphatic carboxylic acid ester. EXAMPLE:7,7-Dimethyl-2-methylenebicyclo[2.2.1]heptan-6-ol. USE:A perfumery component of a perfumery composition. It has fresh woody note accompanying refreshing comphor-like top note, and iris-like perfume in the form of acetate or green note and woody note accompanying balsam-like feeling as a propionic acid ester. It has strong diffusibility and perfume-retainability, and harmonizes well with various other perfumery materials. PREPARATION:A lower aliphatic carboxylic acid ester of the titled compound can be produced by the electrolytic oxidation of cyclofenchene in a lower aliphatic carboxylic acid. The ester is hydrolyzed to obtain 7,7-dimethyl-2-methylenebicyclo[2.2.1]heptan-6-ol.
Patients that are enrolled into this cohort will receive IS minimization if virus infection or side effects of IS was found. The strategy of IS minimization will follow the "Clinical guidelines for pediatric liver transplantation in China(2015)". Blood test and liver biopsy will be conducted to monitor liver function and intrahepatic pathological conditions. If IS is ceased for more than one year without liver dysfunction or signs of acute rejection in liver biopsy, immune tolerance was considered reached.
<P>PROBLEM TO BE SOLVED: To provide a composition wherein sterilizing power and/or detergent power of a chlorous acids compound are considerably enhanced.  <P>SOLUTION: This water-based composition contains a chlorous acids compound, glycerol, and a phosphoric acid compound. The water-based composition is used for a sterilizing solution for contact lenses, an antiseptic solution for contact lenses, a washing solution for contact lenses, a rinsing solution for contact lenses, or a saline solution for contact lenses. The water-based composition is used for a multi-purpose solution for contact lenses. The water-based composition is used for an ophthalmic solution, in particular, an ophthalmic solution for dry eyes.  <P>COPYRIGHT: (C)2009,JPO&INPIT
All eligible patients will receive a total of five treatment weeks, each consisting of approximately 5 days. Prior to therapy, patients will undergo apheresis for DC preparation. DC-Tumor vaccines will be frozen in 90% pooled human AB serum/ 10% DMSO to be used for treatment Patients will be dosed with bevacizumab (10mg/kg, Genentech) intravenously every two weeks beginning four weeks prior to the first vaccine. Each treatment week includes ultrasound guided intranodal DC-vaccine injection (1 X 107 cells/1mL), followed by 5 days of continuous intravenous infusion of IL-2 (18 MiU/m2, Novartis), and three subcutaneous injections of IFNa-2b (6 MiU, Schering -Plough Corp.) (every other day). The first two treatment weeks, the induction phase, will be separated by a 9 day rest. Three additional treatment weeks, the maintenance phase, will be separated by 23 rest days.
BACKGROUND: Data regarding the diagnostic value of ultrasound (US)-determined fluid film and joint aspiration prior to revision total hip arthroplasty for suspected periprosthetic joint infections (PJIs) are limited. This study aimed to analyze the value of US-determined fluid film, characterized the preoperative and intraoperative microbiological spectrum and resistance patterns, and compared the concordance between preoperative synovial fluid and intraoperative culture results.
METHODS: We analyzed 366 US examinations from 324 patients prior to revision total hip arthroplasty. Selected cases were grouped into clearly infected, noninfected, and inconclusive cohorts, according to the International Consensus Meeting 2018 Criteria. For US-determined fluid film <1 mm, no aspiration was performed based on our institutional protocol. Patients were grouped into no aspiration (144 of 366; [39.3%]), dry tap (21 of 366; [5.7%]), and a successful tap (201 of 366; [54.9%]). The microbiological spectrum and antibiograms were compared between preoperative and intraoperative results.
RESULTS: The absence of US-determined fluid film showed no correlation with the presence of a hip PJI. Overall, 31.9% cases of the no-aspiration group had a PJI. In total, 13.5% discrepancies were found between successful taps and intraoperative cultures. The most prevalent microorganisms in preoperative synovial fluid were Staphylococcus epidermidis and Staphylococcus aureus (20.8%), while intraoperatively S. epidermidis (26.3%) and Cutibacterium acnes (14.5%) were leading. Additional microorganisms were identified in 32.5% of intraoperative cultures. There were no differences between resistance patterns of preoperative and intraoperative concordant microorganisms.
CONCLUSIONS: Absence of US-determined fluid film cannot rule out the presence of a hip PJI. Combined microbiological results from hip US aspirations and subsequent surgical procedures are crucial to design an effective treatment for suspected hip PJI.
INTRODUCTION: Interstitial fibrosis and tubular atrophy are leading causes of renal allograft failure. Shear wave elastography could be a promising noninvasive method for providing information on the state of the kidney, with specific regard to fibrosis but currently available data in the literature are controversial. Our study aimed to analyze the correlation between shear wave elastography and various kidney dysfunction measures.
METHODS: This review was registered on PROSPERO (CRD42021283152). We systematically searched three major databases (MEDLINE, Embase, and CENTRAL) for articles concerning renal transplant recipients, shear wave elastography, fibrosis, and kidney dysfunction. Meta-analytical calculations for pooled Pearson and Spearman correlation coefficients (r) were interpreted with 95% confidence intervals (CIs). Heterogeneity was tested with Cochran's Q test. I2 statistic and 95% CI were reported as a measurement of between-study heterogeneity. Study quality was assessed with the QUADAS2 tool.
RESULTS: In total, 16 studies were included in our meta-analysis. Results showed a moderate correlation between kidney stiffness and interstitial fibrosis and tubular atrophy, graded according to BANFF classification, on biopsy findings for pooled Pearson (r = 0.48; CI: 0.20, 0.69; I2 = 84%) and Spearman correlations (r = 0.57; CI: 0.35, 0.72; I2 = 74%). When compared to kidney dysfunction parameters, we found a moderate correlation between shear wave elastography and resistive index (r = 0.34 CI: 0.13, 0.51; I2 = 67%) and between shear wave elastography and estimated Glomerular Filtration Rate (eGFR) (r = -0.65; CI: - 0.81, - 0.40; I2 = 73%). All our outcomes had marked heterogeneity.
CONCLUSION: Our results showed a moderate correlation between kidney stiffness measured by shear wave elastography and biopsy results. While noninvasive assessment of kidney fibrosis after transplantation is an important clinical goal, there is insufficient evidence to support the use of elastography over the performance of a kidney biopsy.
Sodium stibogluconate 900 mg/m2/day will be given on Monday through Friday every other week for the first 16 weeks of the study (on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th and 15th weeks). On the alternate weeks patients will not receive any study treatment.
Subjects will consume the RS prebiotic daily for 4 weeks. A dose escalation will be used with subjects taking 4g of the prebiotic for the first 4 days, 7g the next 3 days and the full dose of 10g on day 8.
Each patient received a comprehensive eye examination, including corrected distance visual acuity (CDVA) preoperatively and the day after surgery, subjective refraction, slit-lamp evaluation, noncontact tonometry (TX-F; Cannon, Tokyo, Japan), and dilated fundus examination. According to the surgery decision made by the three surgeons based on the slit lamp biomicroscopy and CDVA, patients were divided into two groups: Surgical and Non-Surgical. The results of the DLI, OSI and average lens density (ALD) were masked to the surgeons. The DLI, OSI, average lens density, LOCS III nuclear opalescence grading, and preoperative CDVA were obtained. Correlations among these parameters were analyzed. ROC curves were used to analyze DLI values to determine a value to separate between surgical and non-surgical cataracts.